Comparative Pharmacology
Head-to-head clinical analysis: GRIFULVIN V versus MONISTAT 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRIFULVIN V versus MONISTAT 5.
GRIFULVIN V vs MONISTAT 5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to microtubule-associated proteins and disrupts fungal mitotic spindle formation, thereby inhibiting fungal cell division. It also interferes with fungal nucleic acid synthesis.
Miconazole inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
500 mg orally once daily (non-microsize formulation) or 250 mg twice daily; typical duration is 4-8 weeks for tinea capitis, 2-6 weeks for tinea corporis, 4-6 weeks for tinea pedis.
Miconazole nitrate 100 mg vaginal suppository inserted once daily at bedtime for 3 days; or 200 mg vaginal suppository once daily at bedtime for 3 days; or 1200 mg vaginal suppository as a single dose.
None Documented
None Documented
Terminal half-life: 9–24 hours. Clinical context: Steady-state achieved in 2–5 days; prolonged in hepatic impairment.
Terminal half-life approximately 24 hours; supports once-daily dosing.
Renal (1% unchanged), fecal (33% as metabolites), biliary (minor). Extensive hepatic metabolism; <1% excreted unchanged in urine.
Primarily fecal (90%) as unchanged drug; renal excretion minimal (<1%).
Category C
Category C
Antifungal
Antifungal